OCE
Oncology Center of Excellence
Coordinates oncology review across the drug, biologic, and device centers — the through-line for solid-tumor and hematologic malignancy programs.
Consultants who know your science, your endpoints, and your division of the agency — not just the regulations around them. We staff by the biology of your program, not a generalist rotation.
Depth, not coverage
A reviewer in oncology weighs a surrogate endpoint differently than one in cardiology. A rare-disease division reads a 40-patient dataset differently than an anti-infectives team reads 4,000. The rulebook is public; the way each division applies it is learned.
Our consultants have sat on the other side of those meetings — in the therapeutic area you’re working in, at the center that will review you. So the strategy we bring already anticipates the questions your program will actually get asked.
The Directory
Sixteen areas of deep expertise. Each links to how we think about its science, its endpoints, and its regulatory path.
Know your reviewer
Your therapeutic area determines which FDA center or office reviews your submission — and each reads the evidence its own way. We place consultants who have worked inside the one that will read yours.
OCE
Coordinates oncology review across the drug, biologic, and device centers — the through-line for solid-tumor and hematologic malignancy programs.
CDER
Small molecules and most therapeutic biologics. The review divisions here run the majority of chronic-disease and specialty programs.
CBER
Vaccines, blood products, and the advanced therapies — cell, gene, and live biotherapeutics — where precedent is thin and the science moves fastest.
CDRH
Devices, in-vitro diagnostics, and software as a medical device — plus the device constituent of every combination product.
Working a combination product or companion diagnostic? Those cross center lines — and the hand-off is where programs stall. We staff for the intercenter path, not just the lead center.
Don’t see your indication? The team is deeper than the page.
Tell us the molecule, the modality, and the meeting on your calendar. We’ll match you to consultants who have been in that room.